Src activity is modulated by oxaliplatin and correlates with outcomes after hepatectomy for metastatic colorectal cancer

BMC Cancer

Gary Gallick⁴  Paul Elvin²  Dipen Maru⁵  Zhi-Qin Jiang³  Michael J Overman³  Nila Parikh⁴  Van K Morris¹  Scott Kopetz³ 

[1]Department of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

[2]AstraZeneca, Wilmington, Delaware, USA

[3]Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

[4]Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 0018-4, Houston, TX 77030, USA

[5]Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

关键词: Focal adhesion kinase;    Src oncogene;    Hepatectomy;    Metastasis;    Colorectal cancer;   

Others  :  1121094
DOI  :  10.1186/1471-2407-14-660

 received in 2014-01-22, accepted in 2014-08-22,  发布年份 2014

【 摘 要 】

Background

The nonreceptor tyrosine kinase Src regulates multiple pathways critical to tumor proliferation, chemoresistance, and epithelial-to-mesenchymal transition. It is robustly activated after acute oxaliplatin exposure and in acquired oxaliplatin resistance in vitro and in vivo, but not after 5-fluorouracil (5-FU) alone. However, activation of Src and its substrate focal adhesion kinase (FAK) in metastatic colorectal cancer treated with oxaliplatin has not been investigated. We retrospectively evaluated the activation of Src and FAK in hepatic metastases of colorectal cancer and correlated these findings with the clinical outcomes of patients treated with oxaliplatin.

Methods

Samples from 170 hepatic resections from patients with metastatic colorectal cancer from two cohorts were examined by IHC for expression of Src, activated Src (pSrc), FAK, and activated FAK (pFAK). Patients in the first cohort (120 patients) were analyzed for immunohistochemical protein expression and for survival outcomes. In the second cohort, tissue was collected from 25 patients undergoing sequential hepatic metastasectomies (n = 50).

Results

In the first cohort, Src activation was positively correlated with pFAK expression (P = 0.44, P < 0.001). Patients pretreated with oxaliplatin and 5-FU demonstrated increased expression of pFAK (P = 0.017) compared with patients treated with 5-FU alone or irinotecan/5-FU. Total Src expression was associated with the number of neoadjuvant cycles of oxaliplatin (P = 0.047). In the second cohort, pFAK expression was higher following exposure to oxaliplatin. When patients were stratified by expression of pFAK and pSrc, an inverse relationship was observed between relapse-free survival rates and levels of both pFAK (21.1 months, 16.5 months, and 7.4 months for low, medium, and high levels of pFAK, respectively; P = 0.026) and pSrc (19.6 months, 13.6 months, and 8.2 months, respectively; P = 0.013). No differences in overall survival were detected.

Conclusions

Patients administered neoadjuvant oxaliplatin demonstrated higher levels of Src pathway signaling in hepatic metastases, a finding associated with poorer relapse-free survival. These results are consistent with prior in vitro studies and support the idea that combining Src inhibition with platinum chemotherapy warrants further investigation in metastatic colorectal cancer.

【 授权许可】

   
2014 Kopetz et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

【 参考文献 】

• [1]Taylor SJ, Shalloway D: Src and the control of cell division. Bioessays 1996, 18(1):9-11.
• [2]Frame MC: Newest findings on the oldest oncogene; how activated src does it. J Cell Sci 2004, 117(Pt 7):989-998.
• [3]Yeatman TJ: A renaissance for SRC. Nat Rev Cancer 2004, 4(6):470-480.
• [4]Thomas SM, Brugge JS: Cellular functions regulated by Src family kinases. Annu Rev Cell Dev Biol 1997, 13:513-609.
• [5]Summy JM, Gallick GE: Src family kinases in tumor progression and metastasis. Cancer Metastasis Rev 2003, 22(4):337-358.
• [6]Roskoski R Jr: Src kinase regulation by phosphorylation and dephosphorylation. Biochem Biophys Res Commun 2005, 331(1):1-14.
• [7]Levin VA: Basis and importance of Src as a target in cancer. Cancer Treat Res 2004, 119:89-119.
• [8]Dehm SM, Bonham K: SRC gene expression in human cancer: the role of transcriptional activation. Biochem Cell Biol 2004, 82(2):263-274.
• [9]Aligayer H, Boyd DD, Heiss MM, Abdalla EK, Curley SA, Gallick GE: Activation of Src kinase in primary colorectal carcinoma: an indicator of poor clinical prognosis. Cancer 2002, 94(2):344-351.
• [10]Avizienyte E, Brunton VG, Fincham VJ, Frame MC: The SRC-induced mesenchymal state in late-stage colon cancer cells. Cells Tissues Organs 2005, 179(1–2):73-80.
• [11]Brunton VG, Ozanne BW, Paraskeva C, Frame MC: A role for epidermal growth factor receptor, c-Src and focal adhesion kinase in an in vitro model for the progression of colon cancer. Oncogene 1997, 14(3):283-293.
• [12]Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbivavar F: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004, 350(23):2335-2342.
• [13]Talamonti MS, Roh MS, Curley SA, Gallick GE: Increase in activity and level of pp60c-src in progressive stages of human colorectal cancer. J Clin Invest 1993, 91(1):53-60.
• [14]Griffiths GJ, Koh MY, Brunton VG, Cawthorne C, Reeves NA, Greaves M, Tilby MJ, Pearson DG, Ottley CJ, Workman P, Frame MC, Dive C: Expression of kinase-defective mutants of c-Src in human metastatic colon cancer cells decreases Bcl-xL and increases oxaliplatin- and Fas-induced apoptosis. J Biol Chem 2004, 279(44):46113-46121.
• [15]Duxbury MS, Ito H, Zinner MJ, Ashley SW, Whang EE: Inhibition of SRC tyrosine kinase impairs inherent and acquired gemcitabine resistance in human pancreatic adenocarcinoma cells. Clin Cancer Res 2004, 10(7):2307-2318.
• [16]George JA, Chen T, Taylor CC: SRC tyrosine kinase and multidrug resistance protein-1 inhibitions act independently but cooperatively to restore paclitaxel sensitivity to paclitaxel-resistant ovarian cancer cells. Cancer Res 2005, 65(22):10381-10388.
• [17]Sharma MR, Wroblewski K, Polite BN, Knost JA, Wallace JA, Modi S, Sleckman BG, Taber D, Vokes EE, Stadler WM, Kindler HL: Dasatinib in previously treated metastatic colorectal cancer: a phase II trial of the University of Chicago phase II consortium. Invest New Drugs 2012, 30(3):1211-1215.
• [18]Kopetz S, Lesslie DP, Dallas NA, Park SI, Johnson M, Parikh NU, Kim MP, Abbruzzese JL, Ellis LM, Chandra J, Gallick GE: Synergistic activity of the SRC family kinase inhibitor dasatinib and oxaliplatin in colon carcinoma cells is mediated by oxidative stress. Cancer Res 2009, 69(9):3842-3849.
• [19]Park J, Meisler AI, Cartwright CA: c-Yes tyrosine kinase activity in human colon carcinoma. Oncogene 1993, 8(10):2627-2635.
• [20]Cartwright CA, Kamps MP, Meisler AI, Pipas JM, Eckhart W: pp60c-src activation in human colon carcinoma. J Clin Invest 1989, 83(6):2025-2033.
• [21]Han NM, Curley SA, Gallick GE: Differential activation of pp 60(c-src) and pp 62(c-yes) in human colorectal carcinoma liver metastases. Clin Cancer Res 1996, 2(8):1397-1404.
• [22]Kypta RM, Goldberg Y, Ulug ET, Courtneidge SA: Association between the PDGF receptor and members of the src family of tyrosine kinases. Cell 1990, 62(3):481-492.
• [23]Baba Y, Nosho K, Shima K, Hayashi M, Meyerhardt JA, Chan AT, Giovannucci E, Fuchs CS, Ogino S: Phosphorylated AKT expression is associated with PIK3CA mutation, low stage, and favorable outcome in 717 colorectal cancers. Cancer 2011, 117(7):1399-1408.
• [24]Irahara N, Baba Y, Nosho K, Shima K, Yan L, Dias-Santagata D, Iafrate AJ, Fuchs CS, Haigis KM, Ogino S: NRAS mutations are rare in colorectal cancer. Diagn Mol Pathol 2010, 19(3):157-163.
• [25]Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P, Bechstein WO, Primrose JN, Walpole ET, Finch-Jones M, Jaeck D, Mirza D, Parks RW, Collette L, Praet M, Bethe U, Van Cutsem E, Scheithauer W, Gruenberger T, EORTC Gastro-Intestinal Tract Cancer Group; Cancer Research UK; Arbeitsgruppe Lebermetastasen und-tumoren in der Chirurgischen Arbeitsgemeinschaft Onkologie (ALM-CAO); Australasian Gastro-Intestinal Trials Group (AGITG); Fédération Francophone de Cancérologie Digestive (FFCD): Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC intergroup trial 40983): a randomised controlled trial. Lancet 2008, 371(9617):1007-1016.